Form 4: Amylyx Pharmaceuticals Director Daphne Quimi Increases Stake in Company
SEC Form 4
Director Daphne Quimi recently acquired additional shares of Amylyx Pharmaceuticals, signaling confidence in the company's future.
Summary
- On May 14, 2024, Daphne Quimi, a director of Amylyx Pharmaceuticals, acquired 2,750 shares of common stock at a price of $1.885 per share.
- Following this transaction, Ms. Quimi directly owns 2,750 shares.
- On May 15, 2024, Ms. Quimi acquired an additional 2,250 shares of common stock at a price of $1.8899 per share.
- Following this transaction, Ms. Quimi directly owns 5,000 shares.
Sentiment
Score: 7
Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's future performance. However, the quantity of shares purchased is relatively small.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's prospects.
Industry Context
This filing reflects insider trading activity, which is closely monitored by investors for signals about a company's prospects. Director purchases are often viewed more favorably than sales.
Stakeholder Impact
- Shareholders may view the director's stock purchase as a positive indicator of the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Daphne Quimi acquired 2,750 shares of common stock at $1.885 per share. |
| 05/15/2024 | Daphne Quimi acquired 2,250 shares of common stock at $1.8899 per share. |
| 05/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.